Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Can Emcure’s Cut-Price Eribulin Dull Halaven In India?

Thu, 04/04/2019 - 12:05am

Emcure has launched a generic version of Eisai’s cancer drug Halaven on the Indian market at a sharp 40% discount to the...

      Related Stories 

Japan Cell, Regenerative Therapy Environment ‘Exciting’ But Ongoing Dialog Needed

Wed, 04/03/2019 - 6:21pm

While the environment for cell and regenerative medicines in Japan is ‘exciting’ and positive, ongoing dialog with policy makers and...

      Related Stories 

Rare Disease Roundtable: Dealing With Pricing Pressure

Wed, 04/03/2019 - 2:28pm

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip...

      Related Stories 

Deal Watch: Editas, BlueRock Ink Cross-Licensing Technology Collaboration

Wed, 04/03/2019 - 2:13pm

Combining Editas’ CRISPR gene-editing technology with BlueRock’s pluripotent stem cell capabilities, the companies hope to leverage each other to create...

      Related Stories 

Roche Confident Spark Therapeutics Acquisition Will Complete In First Half

Wed, 04/03/2019 - 8:51am

US financial regulators have not been quick at reviewing Roche’s multi-billion dollar acquisition of gene therapy biotech Spark Therapeutics, but...

      Related Stories 

AgomAb Raises €21M Series A To Regenerate Damaged Tissues

Tue, 04/02/2019 - 11:03pm

Ghent, Belgium-based start-up, AgomAb Therapeutics NV secures funds and license to develop HGF-mimetic agonistic monoclonal antibodies for regeneration of damaged...

      Related Stories 

Allergan Improves Safety Of Abicipar, But Not Enough Compared To Lucentis, Eylea

Tue, 04/02/2019 - 1:53pm

Allergan has been developing abicipar to provide less-frequent dosing in neovascular AMD, but despite success in reducing intraocular inflammation with...

      Related Stories 

Expert View: No-Deal Brexit's Legal Fallout For Pharma

Tue, 04/02/2019 - 9:08am

Dr Jonathan Atkinson, partner at the UK-based intellectual property law firm HGF Ltd, sums up key expectations around legal, patent-related...

      Related Stories 

Pierre Fabre Boosts Oncology Offering In Europe With Puma Deal

Tue, 04/02/2019 - 7:02am

Another major deal with a US biotech has seen France’s Pierre Fabre exclusively licensing Puma’s Nerlynx for development and commercialization...

      Related Stories 

Novartis Prioritizes Gene Therapy Production With AZ Facility Buy

Tue, 04/02/2019 - 6:26am

A US plant will become the largest of four state-of-the-art sites involved in manufacturing of Novartis unit Avexis' gene therapies...

      Related Stories 

BerGenBio Adds Another Brick To AXL Inhibitor Bemcentinib’s AML Potential

Tue, 04/02/2019 - 6:16am

As the most advanced AXL inhibitor product in the global pipeline, BerGenBio’s bemcentinib has continued to show encouraging data in...

      Related Stories 

Publisher's Spotlight: The 2019 Scrip Awards Is Now Open For Nominations

Tue, 04/02/2019 - 2:08am

Come and celebrate your vital contribution to improving human health worldwide – the 2019 Scrip Awards is now open for...

      Related Stories 

Pages